Focusing on novel traits of cannabis plants, a partnership among CannaPacific, Xing Technologies and Newcastle University, seeks to develop “one of the most advanced medical cannabis genomic breeding programs in the world,” notes a statement from CannaPacific.
It is hoped that engineering novel cannabis varieties with less variability and more productivity will lead to new low-cost medicinal formulations and improved delivery of products.
“There is over 100 cannabinoids in the plant, and many are still yet to be exploited,” says CannaPacific chief executive Joshua Dennis, according to the Newcastle Herald. “THC and CBD are there in the highest quantities, but there is a whole gamut of other cannabinoids in the plant in really low quantities,” Dennis says.
Minor cannabinoids, some of which have been shown to have medicinal benefits or promise, are present in strains. The trick will be identifying the new varieties with more of them.
By developing genetic markers, it…